Short answer
Incyte (INCY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $1.6B (up 14.0% year over year) with net income of −$785M.
Q3 2026 key financials · XBRL
- Revenue
- $1.6B
- +14.0% YoY · −7.0% QoQ
- Net income
- −$785M
- −285.0% YoY · −234.0% QoQ
- Operating margin
- -45.5%
- EPS (diluted)
- −$3.78
- −279.1% YoY · −234.5% QoQ
Source: XBRL data from the Incyte (INCY) Q3 2026 10-Q on SEC EDGAR. USD.
Incyte Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Total revenue $1,557.2M, up $191.2M YoY from $1,366.0M
- Net loss $784.8M vs net income $424.2M YoY, driven by $1.23B Vega IPR&D expense
- Best product OPZELURA, sales $254.9M vs $188.0M; worst ICLUSIG, $33.5M vs $37.6M
- Cash, equivalents and marketable securities $3.9B; operating cash flow $201.7M vs $870.2M YoY
- Outlook: cash resources adequate for foreseeable future; FDA povorcitinib decision anticipated first quarter 2027
Risk Factors
- Newly added acquisition risk: July 2026 Vega Therapeutics acquisition creates integration, compliance and contingent-liability exposure
- Most material patent risk: Generic JAKAFI manufacturers’ challenges remain pending against patents expiring December 2028
- Regulatory risk: Inflation Reduction Act manufacturer discount obligations increase as Medicare Part D provisions phase out
- Near-term commercial risk: OPZELURA generic challenges remain pending against patents expiring in 2031 and 2040
- Financial risk: Global operations expose revenues and net income to unfavorable foreign-currency fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Incyte quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.